Related by context. All words. (Click for frequent words.) 80 tolerability profile 77 pharmacokinetic profile 76 pharmacokinetics 74 efficacy 73 safety tolerability 73 pharmacokinetic 72 pharmacokinetic profiles 72 immunogenicity 72 dosing regimens 72 pharmacokinetics PK 70 analgesic efficacy 70 pharmacodynamic 70 efficacy tolerability 69 monotherapy 69 antiviral activity 68 pharmacodynamic profile 68 Phase Ib 68 tolerability profiles 68 safety tolerability pharmacokinetics 67 pharmacodynamics 67 placebo controlled 67 pharmacokinetic properties 67 active comparator 67 antitumor activity 66 antiviral efficacy 66 Phase 2b study 66 dose escalation trial 66 Phase 1b 66 tolerated dose MTD 66 Phase 2a trial 65 teriflunomide 65 tiotropium 65 SCH # 65 safety tolerability pharmacokinetic 65 Phase Ib clinical 65 double blind placebo 65 Phase 1b clinical 65 pharmacodynamic properties 65 pharmacokinetic PK 64 Phase 1b trial 64 Phase IIa 64 efficacy endpoints 64 dosing 64 Tolerability 64 pharmacodynamics PD 64 oral bioavailability 64 dose regimens 64 pharmacodynamic PD 64 dose escalation study 64 anti leukemic 64 mg dose 64 bioavailability 64 dosing regimen 64 ascending doses 63 CYT# 63 PXD# 63 dose escalation 63 secondary efficacy endpoints 63 ascending dose 63 phase Ib 63 administered subcutaneously 63 Phase 2b trial 63 dosage regimens 63 INCB# [001] 63 diabetic neuropathic pain 63 posaconazole 63 Phase IIb 63 Phase 2a clinical 63 bosentan 63 pharmacokinetic PK profile 63 riociguat 63 chlorambucil 63 maximally tolerated dose 63 Phase IIa trial 63 viral kinetics 63 dose cohorts 63 IMGN# 63 Phase 2a 63 LEXIVA r 63 PEG Interferon lambda 62 pharmacokinetics pharmacodynamics 62 tolerability pharmacokinetics 62 nab paclitaxel 62 vinorelbine 62 Phase 2b clinical 62 favorable tolerability 62 placebo controlled clinical 62 Phase 1a 62 Phase IIa clinical 62 dosing schedules 62 ACTEMRA TM 62 Phase IIb clinical 62 pharmacodynamic effects 62 pertuzumab 62 mg BID 62 ritonavir boosted 62 favorable pharmacokinetic profile 62 decitabine 62 vicriviroc 62 INCB# [002] 62 CIMZIA TM 62 docetaxel 62 ACTEMRA 62 dose regimen 62 bendamustine 62 APTIVUS 62 Phase III clinical 62 phase IIb clinical 62 oral prodrug 62 RDEA# 62 dose limiting toxicities 62 ganetespib 62 Traficet EN 62 adalimumab 61 primary endpoint 61 gemcitabine 61 PSN# [002] 61 #mg dose [001] 61 Phase 2b 61 melphalan prednisone 61 AZILECT R 61 eltrombopag 61 tanespimycin 61 placebo controlled studies 61 phase IIa clinical 61 multiple ascending dose 61 oral dosing 61 carboplatin paclitaxel 61 pharmacokinetic parameters 61 TMC# [001] 61 Pharmacokinetics PK 61 Phase Ib study 61 bronchodilation 61 eculizumab 61 PRTX 61 ISIS # 61 prucalopride 61 preclinical studies 61 randomized double 61 desvenlafaxine succinate 61 viral kinetic 61 mg QD 61 pomalidomide 61 etanercept 61 carboplatin 61 mapatumumab 61 coadministration 61 Cloretazine R VNP#M 61 noninferiority 61 LEP ETU 61 vidofludimus 61 Azedra 61 Pegasys ® 61 investigational compound 61 randomized placebo controlled 61 NP2 Enkephalin 61 beclomethasone dipropionate 61 nitazoxanide 61 pharmacokinetic characteristics 61 CANCIDAS 61 GLYX 61 KRN# 61 telbivudine 61 ORMD 60 LEVADEX 60 single ascending dose 60 FOLPI 60 subcutaneous formulation 60 mcg dose 60 tipranavir 60 JAK inhibitor 60 oral diclofenac 60 rFIXFc 60 orally administered 60 reactogenicity 60 forodesine 60 azacitidine 60 dose cohort 60 glatiramer acetate 60 clinical trial 60 PREZISTA r 60 Phase IIb trial 60 systemic absorption 60 insulin detemir 60 Alocrest 60 fluticasone furoate 60 potent antiviral 60 BAY #-# 60 apremilast 60 CIMZIA ™ 60 celgosivir 60 PRT# 60 CoFactor 60 sorafenib Nexavar 60 edoxaban 60 ANA# 60 oral rivaroxaban 60 phase IIb 60 RE SURGE 60 virologic response 60 IPX# 60 MGCD# [002] 60 cannabinor 60 limiting toxicity 60 sitagliptin 60 Secondary endpoints 60 pharmacokinetic pharmacodynamic 60 Phase Ia 60 Phase Ib II 60 HGS# 60 FOLFOX 60 Sym# 60 Zenvia 60 galiximab 60 HGS ETR1 60 subcutaneously administered 60 bicifadine 60 administered orally 60 elotuzumab 60 plus gemcitabine 60 RG# [001] 60 varespladib 60 lubiprostone 60 double blinded placebo 60 NGX# 60 Ophena TM 60 enzastaurin 59 alvimopan 59 #mg BID [003] 59 secondary endpoints 59 intermittent dosing 59 INC# 59 dosing frequency 59 tolvaptan 59 pharmacokinetic studies 59 peginterferon alfa 2a 59 Zoraxel 59 Locteron 59 PROMACTA 59 blind placebo controlled 59 APTIVUS r 59 non inferiority 59 torezolid phosphate 59 mycophenolate mofetil 59 dasatinib 59 PS# [001] 59 dabigatran etexilate 59 Pharmacokinetic 59 obatoclax 59 CaPre TM 59 sustained virologic response 59 AEGR 59 afatinib 59 vandetanib 59 teduglutide 59 Zerenex 59 urate lowering 59 plus ribavirin 59 glucose lowering 59 CR# vcMMAE 59 placebo controlled Phase 59 clinically meaningful 59 MAP# 59 CIMZIA TM certolizumab pegol 59 temozolomide 59 inhibitor RG# 59 zonisamide SR 59 certolizumab 59 VELCADE 59 elagolix 59 achieved statistical significance 59 phase 2a 59 imetelstat 59 Serdaxin 59 oxycodone CR 59 GRN#L 59 LY# [003] 59 oral FTY# 59 VAPRISOL 59 Amrubicin 59 evaluating tivozanib 59 picoplatin 59 relapsing multiple sclerosis 59 protease inhibitor PI 59 visilizumab 59 tapentadol ER 59 tasimelteon 59 amrubicin 59 FTY# 59 biodistribution 59 intravenous dosing 59 DU #b 59 blind randomized placebo 59 Laquinimod 59 investigational oral 59 preclinical efficacy 59 antithrombotic 59 aflibercept 59 limiting toxicity DLT 59 ibandronate 59 Golimumab 59 biologic therapy 59 oral formulation 59 rHuPH# 59 JANUVIA 59 ofatumumab 59 mertansine 59 ataluren 59 lacosamide 59 Efficacy 59 LEXIVA 59 DermaVir Patch 59 ADAGIO study 59 PEG PAL 59 tocilizumab 59 GAMMAGARD 59 optimal dosing 59 ATACAND 59 AZILECT 59 FTY# fingolimod 59 axitinib 59 oral deforolimus 59 Toxicities 59 velafermin 59 plus dexamethasone 59 baminercept 58 placebo 58 FOSRENOL R 58 glycopyrrolate 58 HuMax EGFr 58 RSD# oral 58 6R BH4 58 DAVANAT 58 peginterferon alfa 2b 58 LY# [002] 58 TMC# C# 58 SYMBICORT 58 salmeterol fluticasone 58 HspE7 58 ancrod 58 Preclinical studies 58 label dose escalation 58 pramlintide 58 randomized Phase III 58 elacytarabine 58 treprostinil 58 CRx 58 docetaxel Taxotere 58 dacarbazine 58 Xanafide 58 LCP AtorFen 58 dexamethasone 58 RoACTEMRA 58 docetaxel chemotherapy 58 orally bioavailable 58 mg doses 58 VA# [002] 58 LIALDA 58 rituximab 58 sunitinib 58 plasma concentrations 58 VELCADE melphalan 58 nebulized formoterol fumarate 58 pegylated interferon alfa 2b 58 hematologic malignancies 58 phase IIa 58 Omacetaxine mepesuccinate 58 Triolex 58 polymerase inhibitor 58 telcagepant 58 CA4P 58 multicenter 58 randomized controlled 58 mcg kg 58 antitumor effect 58 R#/MEM # 58 adalimumab Humira 58 APD# 58 Doxil ® 58 primary hypercholesterolemia 58 temsirolimus 58 sunitinib malate 58 Phase IIb trials 58 levetiracetam 58 romidepsin 58 Tolvaptan 58 glufosfamide 58 RE LY ® 58 budesonide 58 Dapagliflozin 58 relapsed refractory multiple myeloma 58 alfa 2a 58 Marqibo 58 pramipexole 58 FOSRENOL ® 58 huC# DM4 58 Perforomist TM Inhalation Solution 58 Multimeric 58 Phase 1a clinical 58 tirofiban 58 RSD# 58 Chemophase 58 Onbrez Breezhaler 58 ORENCIA ® 58 brivaracetam 58 ZYBRESTAT 58 IMC A# 58 PRECiSE 58 #mg dose [003] 58 TELINTRA 58 erythropoietic 58 TELCYTA 58 lomitapide 58 bortezomib 58 COPAXONE R 58 uric acid lowering 58 relapsing remitting multiple sclerosis 58 TMC# r 58 IDX# 58 pitavastatin 58 sirolimus eluting stent 58 cell lymphoma CTCL 58 telaprevir dosing 58 fosamprenavir 58 Phase IIIb clinical 58 placebo controlled Phase III 58 NVA# 58 albinterferon alfa 2b 58 placebo controlled clinical trials 58 combinability 58 Panzem R NCD 58 cytarabine 58 Debio 58 Bronchitol 58 pharmacokinetic equivalence 58 Bezielle 58 lopinavir r 58 pharmacokinetic PK study 58 pioglitazone 58 REMICADE ® 58 Imprime PGG 58 Taxotere ® 58 neratinib 58 ADX# 58 CLARITY study 58 INCB# [003] 58 tezampanel 58 peg IFN 58 comparator arm 58 Archexin 58 tivozanib 58 Targretin 58 fluconazole 58 Protelos 58 Interferon alpha 58 MIRCERA 57 tapentadol IR 57 rNAPc2 57 multicenter randomized placebo controlled 57 pivotal Phase III 57 alvespimycin 57 DAPT 57 DexaSite 57 indacaterol 57 TAXUS VI 57 pegylated interferon 57 randomized Phase 57 EVIZON 57 HCV SPRINT 57 systemically administered 57 solifenacin 57 rotigotine 57 davunetide intranasal AL 57 EFAPROXYN 57 ciclesonide 57 pramlintide metreleptin combination 57 ARIKACE 57 nonclinical studies 57 dosed orally 57 heavily pretreated 57 safinamide 57 prospectively defined 57 #mg BID [001] 57 Rasilez Tekturna 57 5 FU 57 clinically relevant 57 μg dose 57 CTAP# Capsules 57 CYPHER ® Stent 57 Phenoptin 57 tiotropium bromide 57 virologic 57 leucovorin 57 teriparatide 57 intravesical 57 immunomodulator 57 AzaSite Plus 57 prospective randomized controlled 57 perifosine 57 docetaxel Taxotere R 57 aripiprazole 57 NEVO ™ 57 interferon alfa 57 secondary endpoint 57 adecatumumab 57 radezolid 57 Androxal TM 57 dose escalation Phase 57 pegylated liposomal doxorubicin 57 allopurinol 57 Inhalation Solution 57 Hyphanox 57 pivotal Phase 57 tacrolimus ointment 57 hyperphenylalaninemia HPA due 57 rivaroxaban 57 insulin glargine 57 PEGylated interferon beta 1a 57 Altastaph 57 demonstrated clinically meaningful 57 interferon alfa 2b 57 DASISION 57 subcutaneous dosing 57 NPH insulin 57 novel VDA molecule 57 solithromycin 57 AGILECT R 57 phase IIb study 57 subcutaneous SC 57 sapacitabine 57 Azixa 57 lixisenatide 57 viral suppression 57 PRX # 57 Phase 2b clinical trials 57 sorafenib 57 TG# [003] 57 BRIM2 57 PEG INTRON 57 bevirimat 57 daunorubicin 57 thromboembolic events 57 nonrandomized 57 Phase #/#a 57 LT NS# 57 dexamethasone Decadron 57 raltegravir 57 COPEGUS 57 irbesartan 57 investigational drug 57 ulimorelin 57 abiraterone acetate 57 alpha 2a 57 Immunogenicity 57 antiepileptic drug 57 gemifloxacin 57 hour bronchodilation 57 neurotoxicity 57 inhaled iloprost 57 gefitinib 57 DLTs 57 pimecrolimus 57 Empatic 57 ENBREL 57 trodusquemine 57 Octreolin 57 COPD exacerbations 57 Antiviral Activity 57 multicenter randomized 57 nucleoside analog 57 S/GSK# 57 events AEs 57 randomized multicenter 57 tenofovir emtricitabine 57 preclinically 57 cariprazine 57 HDAC inhibitor 57 ribavirin RBV 57 renal toxicity 57 relapsed SCLC 57 primary endpoints 57 Alpharadin 57 Etoposide 57 dosage regimen 57 LCP Tacro 57 idraparinux 57 erlotinib Tarceva ® 57 abacavir lamivudine 57 dosing cohort 57 MYCAMINE 57 ADVANCE PD 57 docetaxel Taxotere ® 57 Carfilzomib 57 metaglidasen 57 SRT# [003] 57 dexpramipexole 57 L PPDS 57 multicentre randomized 57 IRX 2 57 bosutinib 57 TAXUS Stent 57 Fludara 57 CBLC# 57 FOLFIRI 57 lopinavir ritonavir 57 MEK inhibitors 57 XGEVA 57 trials RCTs 57 RLY# 57 Phase III clinical trials 57 QLT# 57 Cimzia ® 57 Mipomersen 57 MoxDuo TM IR 57 mitoxantrone 57 novel histone deacetylase 57 randomized clinical trials 56 LibiGel ® 56 aclidinium 56 anticancer activity 56 Cloretazine 56 antiviral potency 56 clinical endpoints 56 Allovectin 7 ® 56 SNRI 56 Tyrima 56 insulin degludec 56 plus methotrexate 56 dose ritonavir 56 opioid induced constipation 56 bavituximab 56 TMC# [002] 56 atazanavir ritonavir 56 USL# 56 topotecan 56 ribavirin 56 iniparib 56 randomized clinical 56 refractory gout 56 atypical antipsychotic 56 prospective randomized 56 tecarfarin 56 Navelbine 56 evaluating REVLIMID 56 Tasimelteon 56 MGCD# [001] 56 angiotensin receptor blocker ARB 56 PMX # 56 XmAb# 56 pegylated interferon alfa 2a 56 Ribavirin 56 Dasatinib 56 MLN# 56 toxicities 56 protease inhibitor 56 AZD# 56 febuxostat 56 pemetrexed 56 glycemic control 56 liver histology 56 micafungin 56 pain palliation 56 tacrolimus 56 budesonide formoterol 56 MAGE A3 ASCI 56 RezularTM 56 Dual Opioid 56 dose proportionality 56 ara C 56 active metabolite 56 FOLFOX6 56 relapsed refractory 56 QD dosing 56 romiplostim 56 milatuzumab 56 bronchodilator 56 mg/m2 dose 56 PEG SN# 56 subcutaneous injections 56 tigecycline 56 cystinosis patients 56 mg kg dose 56 parathyroid hormone PTH 56 KAPIDEX 56 Darusentan 56 clevidipine 56 cardiac toxicity 56 Afatinib 56 Elocalcitol 56 fondaparinux 56 lisdexamfetamine dimesylate 56 C1 INH 56 ocrelizumab 56 Perifosine 56 plus prednisone 56 clinically meaningful efficacy 56 opioid induced bowel dysfunction 56 tgAAC# 56 demonstrated statistically significant 56 DOXIL 56 REVLIMID lenalidomide 56 ProLindac 56 omega interferon 56 tobramycin 56 Tarceva TM 56 Amigal 56 candesartan cilexetil 56 blinded placebo controlled 56 otelixizumab 56 ELACYT 56 antitumor effects 56 NATRECOR ® 56 paricalcitol 56 recurrent genital herpes 56 PF # [001] 56 double blinded randomized 56 linaclotide 56 interferon beta 56 #mg doses [002] 56 valopicitabine 56 darunavir ritonavir 56 AEG# 56 oral antiviral 56 convenient dosing regimen 56 topical formulation 56 paliperidone palmitate 56 functional dyspepsia 56 Perforomist ™ Inhalation Solution 56 liposomal formulation 56 CCX# 56 zalutumumab 56 proton pump inhibitor PPI 56 Copegus ribavirin 56 tipranavir r 56 Phase III trials 56 platelet inhibitor 56 CG# [003] 56 DP b# 56 KRAS status 56 Phase #b/#a 56 Alzhemed TM 56 pharmacodynamic profiles 56 MoxDuo IR 56 virological response 56 vorinostat 56 ISTODAX 56 calcineurin inhibitors 56 regorafenib 56 selective modulator 56 masked placebo controlled 56 REMINYL ® 56 blind randomized 56 dose escalation clinical 56 blinded randomized placebo controlled 56 clinical trials Multikine 56 Pemetrexed 56 #mg QD [002] 56 boosted protease inhibitor 56 custirsen 56 methotrexate MTX 56 Engerix B 56 everolimus eluting stents 56 Adlea 56 weekly subcutaneous injections 56 sorafenib Nexavar ® 56 Primary endpoints 56 crizotinib PF # 56 immunomodulatory therapy 56 Welchol 56 Panzem R 56 deferiprone 56 primary efficacy endpoints 56 selegiline 56 acting muscarinic antagonist 56 mGluR5 NAM 56 sunitinib Sutent ® 56 ISENTRESS 56 Linaclotide 56 Peginterferon 56 CorVue ™ 56 antitumor efficacy 56 antiarrhythmic drug 56 dose cytarabine 56 efficacy endpoint 56 therapeutic regimens 56 NXL# 56 OncoVEX GM CSF 56 HCV RESPOND 2 56 abatacept 56 octreotide 56 Phase #b/#a trial 56 esomeprazole 56 ruxolitinib 56 Durezol 56 RAPAFLO R 56 interferon gamma 1b 56 peginterferon 56 aripiprazole Abilify 56 relapsed MM 56 Elitek 56 paclitaxel eluting stents 56 TG# [001] 56 Aclidinium 56 LDL lowering 56 Oral NKTR 56 randomized controlled clinical 56 antidepressant efficacy 56 Q#IR 56 TYGACIL 56 highly immunogenic 56 AMITIZA 56 bupropion SR 56 NOXAFIL 56 Eltrombopag 56 ARRY 56 oritavancin 56 COMFORT II 56 erlotinib 56 lenalidomide dexamethasone 56 surrogate endpoint 56 olmesartan 56 bifeprunox 56 pegylated interferon alfa 56 miconazole 56 Gabapentin GR 56 ELND# 56 neurologic progression 56 lamivudine 56 MoxDuo 56 glycemia 56 Pharmacokinetic PK 56 budesonide foam 56 iclaprim 56 refractory CLL 56 bioequivalence 56 Tekamlo 56 multicenter randomized double 56 FOLOTYN 56 alicaforsen enema 56 seliciclib 56 AVONEX ® 56 long acting muscarinic 56 Bortezomib 56 mesalamine 56 plasma pharmacokinetics 56 laquinimod 56 liposome injection 56 AP# [003] 56 telmisartan 56 metastatic renal cell carcinoma 56 virus HCV protease inhibitor 56 #mg/day [001] 56 oral iron chelator 56 Virulizin ® 55 retapamulin 55 reslizumab 55 SILENOR TM 55 evaluable patients 55 rALLy trial 55 dacetuzumab 55 leukemia AML 55 mg TID 55 dirucotide 55 Adalimumab 55 randomized controlled clinical trials 55 HGS ETR2 55 eprotirome 55 Monotherapy 55 preclinical models 55 Combo Stent 55 zileuton 55 factor Xa inhibitor 55 nucleotide analog 55 ARCOXIA 55 lintuzumab 55 cangrelor 55 FOLPI regimen 55 oxaliplatin 55 aliskiren 55 lanthanum carbonate 55 estramustine 55 fosbretabulin 55 EOquin TM 55 metformin HCl 55 cediranib 55 PLX PAD 55 elvitegravir 55 patients evaluable 55 SPRYCEL 55 idarubicin 55 cilengitide 55 OMNARIS HFA 55 Pegasys plus Copegus 55 delafloxacin 55 CCR5 antagonist 55 #mg/m# [001] 55 HER2 positive metastatic breast 55 GFT# 55 AVE# 55 TLK# 55 HQK 55 Tamibarotene 55 imatinib therapy 55 chronic HCV infection 55 standard chemotherapy regimen 55 amphotericin B 55 MORAb 55 depsipeptide 55 AQ4N 55 Denufosol 55 pegylated interferons 55 free survival PFS 55 Sandostatin LAR 55 IFN beta 55 VIRAMUNE XR 55 Preclinical studies suggest 55 SPIRIVA HandiHaler 55 MyVax R 55 oral ridaforolimus 55 trospium 55 rapid virologic response 55 motesanib 55 GAMMAGARD LIQUID 55 ENMD # 55 ToGA 55 follicular lymphoma FL 55 timolol 55 TASKi2 55 TNF inhibitor 55 certolizumab pegol 55 rosuvastatin #mg 55 CRLX# 55 mRCC 55 TPI ASM8 55 Candesartan 55 intravenously administered 55 APOPTONE 55 Vicinium TM 55 eliglustat tartrate 55 G CSF 55 sorafenib tablets 55 Tiotropium 55 thymalfasin 55 pharmacokinetic interactions 55 oral renin inhibitor 55 myopathy rhabdomyolysis 55 SCIg 55 olaparib 55 Ophena 55 lipid parameters 55 APRISO 55 tasocitinib 55 IIa trial 55 inhaled corticosteroid ICS 55 placebo controlled randomized 55 pharmacodynamic endpoints 55 relapsed myeloma 55 insulin lispro 55 Rivaroxaban 55 gemcitabine Gemzar ® 55 oxymorphone ER 55 huN# DM1 55 receptor antagonists 55 ganaxolone 55 Zavesca R 55 QVA# 55 low dose dexamethasone 55 Blinatumomab 55 BNC# 55 Vidaza azacitidine 55 non selective NSAIDs 55 octreotide LAR 55 constipation OIC 55 NLX P# 55 Free Survival PFS 55 Aptivus ® 55 tolterodine 55 cefepime 55 renal function 55 tipifarnib 55 randomized 55 ProSavin 55 AeroLEF TM 55 ILLUMINATE 55 TORISEL 55 ERBITUX 55 QAB# 55 ruboxistaurin 55 inecalcitol 55 denufosol 55 8mg/kg 55 placebo controlled trials 55 INVEGA ® 55 composite endpoint 55 MBP# [001] 55 mecamylamine 55 ARIXTRA 55 Ostarine 55 label multicenter